A Robust ROS Generation Strategy for Enhanced Chemodynamic/Photodynamic Therapy via H 2 O 2 /O 2 Self‐Supply and Ca 2+ Overloading
The efficacy of cancer therapy with reactive oxygen species (ROS) as the main therapeutic medium suffers from a deficiency of oxy‐substrates, for example, insufficient endogenous hydrogen peroxide (H 2 O 2 ) in chemodynamic therapy (CDT) and inherent hypoxia in photodynamic therapy (PDT). Herein, a...
Gespeichert in:
Veröffentlicht in: | Advanced functional materials 2021-12, Vol.31 (50) |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The efficacy of cancer therapy with reactive oxygen species (ROS) as the main therapeutic medium suffers from a deficiency of oxy‐substrates, for example, insufficient endogenous hydrogen peroxide (H
2
O
2
) in chemodynamic therapy (CDT) and inherent hypoxia in photodynamic therapy (PDT). Herein, a smart polyethylene glycol (PEG)‐ylated nanosystem CaO
2
@ZIF‐Fe/Ce6@PEG (abbreviation as CaZFCP) is constructed to achieve H
2
O
2
/O
2
self‐supply and Ca
2+
overloading in tumor cells simultaneously for enhanced CDT/PDT. Under the weakly acidic tumor microenvironment, the activity components inside CaZFCP, that is, CaO
2
nanoparticles, Fe
2+
, and photosensitizer Chlorin e6 (Ce6) are released by the degradation of zeolitic imidazole framework‐90 (ZIF‐90). Thereinto, CaO
2
nanoparticles are further decomposed to generate H
2
O
2
and O
2
, which alleviates both the insufficient endogenous H
2
O
2
and hypoxia in tumor area, thus enhancing the efficiency of CDT and PDT by producing more hydroxyl radicals and singlet oxygen. Furthermore, Ca
2+
overloading induced by the decomposition of CaO
2
is available for amplifying intracellular oxidative stress, resulting in mitochondrial dysfunction, which further improves the efficacy of combined CDT/PDT. In vitro and in vivo experimental results confirm excellent tumor inhibition effect, which also provides a facile paradigm in ROS‐involved cancer therapies. |
---|---|
ISSN: | 1616-301X 1616-3028 |
DOI: | 10.1002/adfm.202106106 |